HPGC Renmintongtai Pharmaceutical Corp600829
▲ PositiveCapitalrelevance
Net profit up 11.60% year-on-year, revenue up 5.03%, and improved margins.

Renmin Tongtai has released its 2026 interim report, with net profit attributable to the parent company at 81.0014 million yuan, an increase of 11.60% compared to the same period last year. The company's total operating revenue was 5.408 billion yuan, up 5.03% year-on-year, marking two consecutive years of growth. Net cash outflow from operating activities was 418 million yuan, the asset-liability ratio fell to 56.55%, gross margin edged up to 8.11%, and ROE stood at 2.62%.
HPGC Renmintongtai Pharmaceutical CorpNet profit up 11.60% year-on-year, revenue up 5.03%, and improved margins.